Айсанов З.Р., Авдеев С.Н., Архипов В.В., Белевский А.С., Лещенко И.В., Овчаренко С.И. и др. Национальные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких: алгоритм принятия клинических решений. Пульмонология. 2017;27(1):13–20. https://doi.org/10.18093/0869-0189-2017-27-1-13-20..
DOI: 10.18093/0869-0189-2017-27-1-13-20
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171. https://doi.org/10.1016/S0140-6736(14)61682-2..
DOI: 10.1016/S0140-6736(14)61682-2
Lopez A.D., Shibuya K., Rao C., Mathers C.D., Hansell A.L., Held L.S. et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27(2):397–412. https://doi.org/10.1183/09031936.06.00025805..
DOI: 10.1183/09031936.06.00025805
Shin S., Bai L., Burnett R.T., Kwong J.C., Hystad P., van Donkelaar A. et al. Air Pollution as a Risk Factor for Incident Chronic Obstructive Pulmonary Disease and Asthma. A 15-Year Population-based Cohort Study. Am J Respir Crit Care Med. 2021;203(9):1138–1148. https://doi.org/10.1164/rccm.201909-1744OC.
DOI: 10.1164/rccm.201909-1744OC
Wang H.H., Cheng S.L. From Biomarkers to Novel Therapeutic Approaches in Chronic Obstructive Pulmonary Disease. Biomedicines. 2021;9(11):1638. https://doi.org/10.3390/biomedicines9111638..
DOI: 10.3390/biomedicines9111638
Caramori G., Casolari P., Barczyk A., Durham A.L., Di Stefano A., Adcock I. COPD immunopathology. Semin Immunopathol. 2016;38(4):497–515. https://doi.org/10.1007/s00281-016-0561-5..
DOI: 10.1007/s00281-016-0561-5
Yang W., Li F., Li C., Meng J., Wang Y. Focus on Early COPD: Definition and Early Lung Development. Int J Chron Obstruct Pulmon Dis. 2021;16:3217–3228. https://doi.org/10.2147/COPD.S338359..
DOI: 10.2147/COPD.S338359
Barr R.G., Bluemke D.A., Ahmed F.S., Carr J.J., Enright P.L., Hoffman E.A. et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010;362(3):217–227. https://doi.org/10.1056/nejmoa0808836..
DOI: 10.1056/nejmoa0808836
Agusti A., MacNee W. The COPD control panel: towards personalised medicine in COPD. Thorax. 2013;68(7):687–690. https://doi.org/10.1136/thoraxjnl-2012-202772..
DOI: 10.1136/thoraxjnl-2012-202772
Soler-Cataluña J.J., Alcázar-Navarrete B., Miravitlles M. The concept of control of COPD in clinical practice. Int J Chron Obstruct Pulmon Dis. 2014;9:1397–1405. https://doi.org/10.2147/COPD.S71370..
DOI: 10.2147/COPD.S71370
Soler-Cataluña J.J., Marzo M., Catalán P., Miralles C., Alcazar B., Miravitlles M. Validation of clinical control in COPD as a new tool for optimizing treatment. Int J Chron Obstruct Pulmon Dis. 2018;13:3719–3731. https://doi.org/10.2147/COPD.S178149..
DOI: 10.2147/COPD.S178149
Miravitlles M., Alcázar B., Soler-Cataluña J.J. The concept of control in chronic obstructive pulmonary disease: Development of the criteria and validation for use in clinical practice. Pulmonologiya. 2020;30(2):135–141. https://doi.org/10.18093/0869-0189-2020-30-2-135-141..
DOI: 10.18093/0869-0189-2020-30-2-135-141
Авдеев С.Н., Невзорова В.А., Куделя Л.М., Кондрашова Н.М., Суханова Г.И., Киняйкин М.Ф. и др. Вопросы тройной терапии в лечении хронической обструктивной болезни легких. Комментарии к алгоритму. Резолюция Совета экспертов от 13.06.18 (Владивосток). Пульмонология. 2019;29(3):365–374. https://doi.org/10.18093/0869-0189-2019-29-3-365-374..
DOI: 10.18093/0869-0189-2019-29-3-365-374
Авдеев С.Н., Трушенко Н.В. Двойная бронходилатация – новая парадигма длительной терапии хронической обструктивной болезни легких. Практическая пульмонология. 2015;(3):24–32. Режим доступа: https://www.elibrary.ru/item.asp?id=25402705.https://www.elibrary.ru/item.asp?id=25402705
Авдеев С.Н., Трушенко Н.В. Двойная бронходилатация – новая парадигма длительной терапии хронической обструктивной болезни легких. Практическая пульмонология. 2015;(3):24–32. Режим доступа: https://www.elibrary.ru/item.asp?id=25402705.https://www.elibrary.ru/item.asp?id=25402705
Williams D.M., Rubin B.K. Clinical Pharmacology of Bronchodilator Medications. Respir Care. 2018;63(6):641–654. https://doi.org/10.4187/respcare.06051..
DOI: 10.4187/respcare.06051
Kruse A.C., Li J., Hu J., Kobilka B.K., Wess J. Novel insights into M3 muscarinic acetylcholine receptor physiology and structure. J Mol Neurosci. 2014;53(3):316–323. https://doi.org/10.1007/s12031-013-0127-0..
DOI: 10.1007/s12031-013-0127-0
Miravitlles M., Baek S., Vithlani V., Lad R. Optimal Bronchodilation for COPD Patients: Are All Long-Acting β₂-Agonist/Long-Acting Muscarinic Antagonists the Same? Tuberc Respir Dis (Seoul). 2018;81(3):198–215. https://doi.org/10.4046/trd.2018.0040..
DOI: 10.4046/trd.2018.0040
Maqsood U., Ho T.N., Palmer K., Eccles F.J., Munavvar M., Wang R. et al. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019;3(3):CD012930. https://doi.org/10.1002/14651858.cd012930.pub2..
DOI: 10.1002/14651858.cd012930.pub2
Calzetta L., Rogliani P., Matera M.G., Cazzola M. A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. Chest. 2016;149(5):1181–1196. https://doi.org/10.1016/j.chest.2016.02.646..
DOI: 10.1016/j.chest.2016.02.646
Meurs H., Dekkers B.G., Maarsingh H., Halayko A.J., Zaagsma J., Gosens R. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm Pharmacol Ther. 2013;26(1):145–155. https://doi.org/10.1016/j.pupt.2012.07.003..
DOI: 10.1016/j.pupt.2012.07.003
Cazzola M., Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23(4):257–267. https://doi.org/10.1016/j.pupt.2010.03.003..
DOI: 10.1016/j.pupt.2010.03.003
Decramer M., Anzueto A., Kerwin E., Kaelin T., Richard N., Crater G. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472–486. https://doi.org/10.1016/S2213-2600(14)70065-7.
DOI: 10.1016/S2213-2600(14)70065-7
Larsson K., Ekberg-Jansson A., Stridsman C., Hanno M., Vanfleteren L.E.G.W. Adherence to Treatment Recommendations for Chronic Obstructive Pulmonary Disease – Results from the Swedish National Airway Register. Int J Chron Obstruct Pulmon Dis. 2021;16:909–918. https://doi.org/10.2147/copd.s300299..
DOI: 10.2147/copd.s300299
Колонтарева Ю.М., Барабанова Е.Н. Комбинированные бронхолитики в терапии ХОБЛ. Лечащий врач. 2016;(12):85–90. Режим доступа: https://www.lvrach.ru/2016/12/15436631?ysclid=l8yjg7ycpy801948698.https://www.lvrach.ru/2016/12/15436631?ysclid=l8yjg7ycpy801948698
Колонтарева Ю.М., Барабанова Е.Н. Комбинированные бронхолитики в терапии ХОБЛ. Лечащий врач. 2016;(12):85–90. Режим доступа: https://www.lvrach.ru/2016/12/15436631?ysclid=l8yjg7ycpy801948698.https://www.lvrach.ru/2016/12/15436631?ysclid=l8yjg7ycpy801948698
Procopiou P.A., Barrett V.J., Bevan N.J., Biggadike K., Box P.C., Butchers P.R. et al. Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem. 2010;53(11):4522–4530. https://doi.org/10.1021/jm100326d..
DOI: 10.1021/jm100326d
Burkes R.M., Panos R.J. Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease. J Exp Pharmacol. 2020;12:589–602. https://doi.org/10.2147/jep.s259328..
DOI: 10.2147/jep.s259328
Hanania N.A., Feldman G., Zachgo W., Shim J.J., Crim C., Sanford L. et al. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012;142(1):119–127. https://doi.org/10.1378/chest.11-2231..
DOI: 10.1378/chest.11-2231
Cazzola M., Segreti A., Matera M.G. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug Des Devel Ther. 2013;7:1201–1208. https://doi.org/10.2147/dddt.s39449..
DOI: 10.2147/dddt.s39449
Celli B., Crater G., Kilbride S., Mehta R., Tabberer M., Kalberg C.J., Church A. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014;145(5):981–991. https://doi.org/10.1378/chest.13-1579..
DOI: 10.1378/chest.13-1579
Donohue J.F., Maleki-Yazdi M.R., Kilbride S., Mehta R., Kalberg C., Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538–1546. https://doi.org/10.1016/j.rmed.2013.06.001..
DOI: 10.1016/j.rmed.2013.06.001
Maleki-Yazdi M.R., Kaelin T., Richard N., Zvarich M., Church A. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108(12):1752–1760. https://doi.org/10.1016/j.rmed.2014.10.002..
DOI: 10.1016/j.rmed.2014.10.002
Feldman G.J., Sousa A.R., Lipson D.A., Tombs L., Barnes N., Riley J.H. et al. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study. Adv Ther. 2017;34(11):2518–2533. https://doi.org/10.1007/s12325-017-0626-4..
DOI: 10.1007/s12325-017-0626-4
Donaldson G.C., Seemungal T.A., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852. https://doi.org/10.1136/thorax.57.10.847..
DOI: 10.1136/thorax.57.10.847
Makris D., Moschandreas J., Damianaki A., Ntaoukakis E., Siafakas N.M., Milic Emili J., Tzanakis N. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med. 2007;101(6):1305–1312.
Kerkhof M., Voorham J., Dorinsky P., Cabrera C., Darken P., Kocks J.W.H. et al. The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline. Int J Chron Obstruct Pulmon Dis. 2020;15:1909–1918. https://doi.org/10.2147/copd.s253812..
DOI: 10.2147/copd.s253812
Vestbo J., Anderson W., Coxson H.O., Crim C., Dawber F., Edwards L. et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J. 2008;31(4):869–873. https://doi.org/10.1183/09031936.00111707..
DOI: 10.1183/09031936.00111707
Jones P.W. St. George’s Respiratory Questionnaire: MCID. COPD. 2005;2(1):75–79. https://doi.org/10.1081/copd-200050513..
DOI: 10.1081/copd-200050513
Donohue J.F. Minimal clinically important differences in COPD lung function. COPD. 2005;2(1):111–124. https://doi.org/10.1081/copd-200053377..
DOI: 10.1081/copd-200053377
Westwood M., Bourbeau J., Jones P.W., Cerulli A., Capkun-Niggli G., Worthy G. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011;12(1):40. https://doi.org/10.1186/1465-9921-12-40..
DOI: 10.1186/1465-9921-12-40
Singh D., Maleki-Yazdi M.R., Tombs L., Iqbal A., Fahy W.A., Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11:1413–1424. https://doi.org/10.2147/copd.s101612..
DOI: 10.2147/copd.s101612